title: [Evaluation of once a day of arbekacin administration to neonates as a new object of peak concentration].
abstract: Once a day of arbekacin (ABK) administrations based on a new object of peak concentration setting on 9-20 microg/mL were performed to 14 neonates. The gestational ages were 27.3 +/- 4.2 weeks. As to the preparing initial dosage, Therapeutic Drug Monitoring Program soft was used. Mean daily dose of 6.2 +/- 0.4 mg/kg bodyweight was administered every 24 to 48 h by 30 min intravenous infusion. Mean serum peak concentrations of ABK and those of trough concentrations were 15.2 +/- 4.3 microg/mL and 2.0 +/- 1.4 microg/mL respectively. The relationship between the measured values (y) and predicted values (x) showed the regression equation y = 0.969 + 0.931x (R2 = 0.769, n = 35), which suggested the usefulness of the dosage design. Overall clinical effectiveness was 78.9% (11/14). There were no obvious adverse effects including abnormal auto auditory brainstem responses and serum creatinine increase. Effectiveness rate and no adverse effects suggested that once a day of ABK therapy in neonate including extremely preterm infant was preferable regimen.
authors.affiliation: Department of Pediatrics, Aizenbashi Hospital.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Kinoshita
mesh_terms: D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000097:blood*; D003982:Dibekacin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood; D006801:Humans; D007231:Infant, Newborn / Q000097:blood*; D007232:Infant, Newborn, Diseases / Q000188:drug therapy; D007235:Infant, Premature, Diseases / Q000188:drug therapy; D055624:Methicillin-Resistant Staphylococcus aureus; D013203:Staphylococcal Infections / Q000188:drug therapy
chemical_list: D000890:Anti-Infective Agents; D003982:Dibekacin; C031986:arbekacin